Novo Nordisk A/S: FDA schedules Advisory Committee meeting for liraglutide 3 mg for the treatment of obesity

Novo Nordisk A/S: FDA schedules Advisory Committee meeting for liraglutide 3 mg for the treatment of obesity

Novo Nordisk A/S: FDA schedules Advisory Committee meeting for liraglutide 3 mg for the treatment of obesity

BAGSVAERD, Denmark, May 20, 2014 (GLOBE NEWSWIRE) -- Novo Nordisk today announced that the US Food and Drug Administration (FDA) has informed the company that an FDA Advisory Committee meeting is tentatively scheduled to be held on 11 September 2014 to discuss the New Drug Application (NDA) for liraglutide 3 mg for the treatment of obesity. The NDA was submitted to the FDA on 20 December 2013.

For further information


  Media:
  Mike Rulis                         +45 4442 3573      [email protected]
  Ken Inchausti (US)             +1 609 514 8316    [email protected]
  Investors:
  Kasper Roseeuw Poulsen    +45 3079 4303      [email protected]
  Jannick Lindegaard Denholt  +45 3079 8519      [email protected]
  Lars Borup Jacobsen           +45 3075 3479      [email protected]
  Daniel Bohsen                      +45 3079 6376      [email protected]
  Frank Daniel Mersebach (US)    +1 609 235 8567    [email protected]

Company announcement No 35 / 2014

Company announcement No 35 / 2014 http://hugin.info/2013/R/1787460/613749.pdf

HUG#1787460

Suggested Articles

Just how expensive can pharmacy medicines get? As much as a buying a luxury car every month, according to GoodRx's latest ranking.

Eisai's Belviq has long struggled to prove itself in obesity. With a recall underway after a cancer risk scare, Belviq's chances may be gone for good.

GBT, a pioneer in the sickle cell field with recently approved Oxbryta, sees an example to emulate as it embarks on its first launch: HIV.